Breast
RAD202
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Solid Tumors.
Trial overview
Clinical Area
Theranostics
Disease
Breast
Disease site
Breast
Study Phase
0
Trial Identifiers
Registration number: NCT06824155
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries